Smith Salley Wealth Management Raises Position in Johnson & Johnson $JNJ

Smith Salley Wealth Management lifted its stake in Johnson & Johnson (NYSE:JNJ) by 11.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,430 shares of the company’s stock after purchasing an additional 5,483 shares during the period. Smith Salley Wealth Management’s holdings in Johnson & Johnson were worth $9,536,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Clayton Financial Group LLC purchased a new position in Johnson & Johnson during the third quarter valued at approximately $28,000. Semmax Financial Advisors Inc. boosted its position in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth $35,000. Finally, Signature Resources Capital Management LLC raised its position in shares of Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $207.07 on Friday. The company’s 50-day moving average price is $200.83 and its 200-day moving average price is $182.27. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a market cap of $498.89 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 2.24 and a beta of 0.36. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s payout ratio is currently 50.19%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wells Fargo & Company increased their price target on Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Barclays raised their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Guggenheim raised their price objective on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, Citigroup boosted their target price on Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $211.25.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.